argenx
ARGX

$494.46

1.67%

Market Cap: 29.6B

About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Employees: 1,148

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 37 analysts

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

7% more capital invested

Capital invested by funds: $12.4B [Q4 2023] → $13.4B (+$918M) [Q1 2024]

1.86% more ownership

Funds ownership: 55.38% [Q4 2023] → 57.24% (+1.86%) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 114

7% less funds holding

Funds holding: 337 [Q4 2023] → 315 (-22) [Q1 2024]

9% less funds holding in top 10

Funds holding in top 10: 22 [Q4 2023] → 20 (-2) [Q1 2024]

14% less call options, than puts

Call options by funds: $90.7M | Put options by funds: $105M

35% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 63

See Fund Rankings

Research analyst outlook

37 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$402

19%

downside

Avg. target

$500

1%

upside

High target

$607

23%

upside

37 analyst ratings

35 positive

95%

2 neutral

5%

0 negative

0%

Guggenheim Yatin Suneja	18%upside $585	Buy Maintained	26 Jul 2024
Oppenheimer Leland Gershell	13%upside $560	Outperform Maintained	26 Jul 2024
Wedbush David Nierengarten	13%upside $560	Outperform Maintained	26 Jul 2024
Wells Fargo Derek Archila	11%upside $547	Overweight Maintained	26 Jul 2024
HC Wainwright & Co. Douglas Tsao	8%upside $533	Buy Maintained	26 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ARGX published over the past 30 days

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART ® Hytrulo following June 21 st FDA approval On track to begin four additional registrational studies across efgartigimod and empasiprubart by end of 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) Regulated Information – Inside Information July 25, 2024 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2024 results and provided a second quarter business update. “We were excited to unveil our ambition for the future of argenx – Vision 2030 – last week, outlining our plan to develop and deliver continued and sustainable innovation for patients,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 financial results and provide a second quarter business update.

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) on July 16, 2024 for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg (5.6ml)/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. “The NMPA approval for efgartigimod SC is yet another key milestone on our journey to expand into new patient populations around the world with our transformative medicine.

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg (5.6ml)/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine.

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Argenx: Strong Setup For Outperformance In 2025

Argenx's shares rose after FDA approval of Vyvgart for the treatment of CIDP. The approval expands the addressable market for Vyvgart, and the company will initially target 12,000 patients in the U.S. who are currently not well controlled on other drugs. The filing with the FDA for the prefilled syringe for Vyvgart was completed, and it represents another potential growth driver in 2025 and a key defensive step in the long-term.

Argenx: Strong Setup For Outperformance In 2025

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Zacks Investment Research

Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?

Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Zacks Investment Research

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Investors Business Daily

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval

Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval

See News Rankings